Your browser doesn't support javascript.
loading
Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report.
Sunagawa, Shawnalyn W; Havens, Joshua P; Podany, Anthony; Walker, Bryan; Scarsi, Kimberly K; Bares, Sara H.
Affiliation
  • Sunagawa SW; College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Havens JP; College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Podany A; Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Walker B; College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Scarsi KK; Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Bares SH; College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Open Forum Infect Dis ; 10(12): ofad604, 2023 Dec.
Article in En | MEDLINE | ID: mdl-38143853
ABSTRACT
As antiretroviral therapy advancements focus on long-acting medications, there is a need to assess the potential impact of drug-drug interactions. We present a real-world case of long-acting cabotegravir/rilpivirine co-administered with intravenous rifampin. The combination resulted in both cabotegravir and rilpivirine concentrations falling below 4 times the protein-adjusted IC90.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Open Forum Infect Dis Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Open Forum Infect Dis Year: 2023 Document type: Article Affiliation country: United States Country of publication: United States